Explore more price target data and ratings for Tilray Brands, Inc. on the Forecasts tab, and track all previous and future analyst recommendations for Tilray Brands, Inc. in the dedicated News Flow.Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This inform…
Record revenue and adjusted EBITDA were achieved, driven by growth across all segments and the BrewDog acquisition. The company strengthened its balance sheet, improved margins, and set guidance for further EBITDA growth in fiscal 2027, with international operations expected to contribute 60% of re…
Record FY 2026 revenue of $915.5M (+11% YoY) and adjusted EBITDA of $61.1M reflect strong growth across all segments, driven by international cannabis, BrewDog acquisition, and disciplined capital allocation. FY 2027 guidance targets $68–$75M adjusted EBITDA and $1.2B revenue run rate.Based on Tilr…
Net revenue grew 11% to $915.5 million, with adjusted EBITDA up 11% to $61.1 million. The company expanded globally through the BrewDog and Lyphe acquisitions, improved margins via cost-saving initiatives, and maintained strong liquidity. Risks include regulatory uncertainty, competition, and suppl…
TLRY (Tilray Brands, Inc.) is set to announce its Q4'25 results on July 28, after the market closes. The earnings are expected to be disclosed at 4:00 PM ET (8:00 PM UTC).For Q4'25, revenue estimate is 246.30 million USD with EPS (earnings per share) anticipated at (0.01) USD. Learn more details at…
Launch of Tilray Medical's first medical cannabis product in Panama strengthens the company's international footprint and supports broader access to regulated cannabinoid-based medicinesPANAMA CITY, July 09, 2026 (GLOBE NEWSWIRE) -- Tilray Medical, a division of Tilray Brands, Inc. NASDAQ:TLRY; TSX…
